/
SMMT
$14.53+$0.21 (+1.47%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$10.9B
776M shares
52-week range
$12.55 – $30.98
11% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.44%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$6.52
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $57.1M | $611.9K | $628.9K | $1.3M | $583.2K | $0 | $0 | $0 |
| Cost of revenue | $24.9K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $56.4M | $611.9K | $628.9K | $1.3M | $583.2K | $0 | $0 | $0 |
| Gross margin | 98.8% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| R&D | $49.1M | $32.8M | $39.0M | $63.1M | $43.0M | $455.3M | $132.4M | $537.7M |
| Operating income | $5.4M | −$22.6M | −$71.6M | −$63.7M | −$59.6M | −$478.2M | −$180.5M | −$1.09B |
| EBITDA | $11.7M | −$21.6M | −$37.1M | −$64.3M | −$51.6M | −$69.5M | −$168.5M | −$1.08B |
| Net income | $10.9M | −$24.0M | −$38.5M | −$65.5M | −$65.2M | −$482.4M | −$176.8M | −$1.08B |
| Net margin | 19.0% | -3920.2% | -6127.6% | -4897.8% | -11174.8% | — | — | — |
| EPS (diluted) | 0.11 | -0.73 | -0.56 | -0.71 | -0.34 | -0.78 | -0.25 | -1.44 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-1.09 | $-1.31–$-0.95 | 8 |
| 2027 | $76M | $-1.11 | $-1.33–$-0.99 | 7 |
| 2028 | $732M | $-0.49 | $-0.99–$0.28 | 7 |
| 2029 | $2.0B | $0.33 | $0.25–$0.40 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.24
Price
$14.53
Implied downside
-98%
Peer comparison
Summit Therapeutics Inc. Common Stock
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
www.smmttx.com- Employees
- 265
- IPO / List date
- Mar 5, 2015
- HQ
- MIAMI, FL
Held by traders on TradeandTell
No one on the platform currently holds SMMT.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in SMMT as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded SMMT yet.
